Inhibition of intraoperative miosis, post-operative trabeculoplasty inflammation in the anterior segment of the eye

Indication for Flurbiprofen

Population group: Suitable for both men and women, only adults (18 years old or older)
Therapeutic intent: Curative procedure

Flurbiprofen is indicated for:

  • the inhibition of intraoperative miosis. Flurbiprofen does not have intrinsic mydriatic properties and does not replace mydriatic agents.
  • the management of post-operative and post-laser trabeculoplasty inflammation in the anterior segment of the eye in patients in whom steroid therapy is not recommended.

For this indication, competent medicine agencies globally authorize below treatments:

1 drop every half hour starting 2 hours before surgery and 24 after surgery 1 drop four times daily

For: Adults (18-64) Elders (65+)

Dosage regimens

Ophthalmic, 1 drops, daily, 4 doses in total. Afterwards, ophthalmic, 1 drops, daily, 4 doses in total, over the duration of 1 to 3 weeks.

Detailed description

For the inhibition of intraoperative miosis, 1 drop is instilled every half hour starting 2 hours before surgery. The final drop should be given not less than 30 minutes before surgery.

To control post-operative and post-laser trabeculoplasty inflammation the dosing regimen above should be followed. Beginning twenty-four hours after surgery, one drop is administered four times daily for at least one week after laser trabeculoplasty or for two to three weeks after other surgery.

Dosage considerations

Flurbiprofen eye drops are administered topically by instillation into the conjunctival sac.

In accordance with standard practice, other topical medication should not be co-administered with flurbiprofen. When administering other topical medications, a minimum interval of 5 minutes between instillations is recommended.

Active ingredient

Flurbiprofen is a propionic acid derivative NSAID which acts through inhibition of prostaglandin synthesis. In humans flurbiprofen has potent analgesic, antipyretic and anti-inflammatory properties.

Read more about Flurbiprofen

Related medicines

Summary of Product Characteristics (SPC) 2019: FROBEN Coated tablet
Summary of Product Characteristics (SPC) 2021: STREFEN HONEY AND LEMON Lozenge
Summary of Product Characteristics (SPC) 2022: OCUFEN Eye drops, solution

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.